Skip to main content

Table 2 Clinical CAR trials targeting T cell malignancies

From: Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions

T cell antigen Clinical Trials Sponsor CAR costimulatory domain Additional intervention Phase Status Ref
CD5 NCT03081910 (MAGENTA) Baylor College of Medicine CD28 None Phase I Recruiting  
CD7 NCT04004637 PersonGen BioTherapeutics    Phase I Recruiting  
NCT04033302 Shenzhen Geno-Immune Medical Institute    Phase I/II Recruiting  
NCT03690011 Baylor College of Medicine CD28 CRISPR/Cas9
CD7-editing
Phase I Not yet recruiting  
NCT02742727 PersonGen BioTherapeutics CD28 and 4-1BB NK-92 cells Phase I/II Unknown  
CD4 NCT03829540 Stony Brook University CD28 and 4-1BB   Phase I Recruiting  
CD30 NCT01192464 Baylor College of Medicine   EBV-specific CTL Phase I Active, not recruiting  
NCT03383965 Immune Cell Inc 2nd generation   Phase I Recruiting  
NCT02690545 UNC Lineberger Comprehensive Cancer Center    Phase I/II Recruiting [62]
NCT02259556 Chinese PLA General Hospital 4-1BB   Phase I/II Recruiting [63]
NCT02958410 Southwest Hospital, China    Phase I/II Recruiting  
NCT03049449 NCI    Phase I Recruiting  
NCT01316146 UNC Lineberger Comprehensive Cancer Center CD28   Phase I Active, not recruiting [55]
NCT02917083 (RELY-30) Baylor College of Medicine CD28   Phase I Recruiting [64]
NCT04008394 Wuhan Union Hospital, China 3rd generation   Phase I Recruiting  
NCT03602157 UNC Lineberger Comprehensive Cancer Center   CCR4 overexpression Phase I Recruiting  
NCT02663297 UNC Lineberger Comprehensive Cancer Center CD28   Phase I Recruiting  
TRBC1 NCT03590574 Autolus Limited   RQR8 safety mechanism Phase I/II Recruiting